Suppr超能文献

在一名患有夏科-马里-图斯病的患者中,使用放疗联合西妥昔单抗成功治疗鼻咽癌。

Successful treatment of nasopharyngeal cancer using radiotherapy with concurrent cetuximab in a patient with Charcot-Marie-Tooth disease.

作者信息

Budure Alexandra Nicoleta, Winquist Eric, Palma David, Correa Rohann Jonathan Mark

机构信息

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

London Health Sciences Centre, London, Ontario, Canada.

出版信息

BMJ Case Rep. 2019 Jul 15;12(7):e228956. doi: 10.1136/bcr-2018-228956.

Abstract

Herein we present a case of a patient with Charcot-Marie-Tooth (CMT) disease who was diagnosed with locally invasive nasopharyngeal carcinoma. In the context of CMT, the use of standard platinum-based radio-sensitising chemotherapy would have been neurotoxic and is contraindicated in patients with CMT. However, no alternate antineoplastic treatment strategies for patients with CMT have been described in the literature. In this case, an innovative approach was taken using radical radiotherapy concurrently with the biological agent cetuximab. The patient did not suffer any neurotoxicity, though he did experience several expected toxicities commonly associated with this regimen. The patient nonetheless completed treatment and has experienced an excellent response both clinically and radiographically and remains disease free.

摘要

在此,我们报告一例患有夏科-马里-图斯(CMT)病的患者,该患者被诊断为局部侵袭性鼻咽癌。在CMT的情况下,使用标准的铂类放射增敏化疗会具有神经毒性,CMT患者禁用。然而,文献中尚未描述针对CMT患者的替代抗肿瘤治疗策略。在本病例中,采用了一种创新方法,即根治性放疗联合生物制剂西妥昔单抗。该患者未出现任何神经毒性,尽管他确实经历了与该治疗方案相关的几种预期毒性。尽管如此,患者完成了治疗,在临床和影像学上均有出色反应,且仍无疾病。

相似文献

2
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.
Acta Oncol. 2018 Mar;57(3):403-411. doi: 10.1080/0284186X.2017.1415462. Epub 2017 Dec 15.
5
The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.
Gynecol Oncol. 2005 May;97(2):710-2. doi: 10.1016/j.ygyno.2005.01.017.
7
Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
Biomed Pharmacother. 2018 Jun;102:681-688. doi: 10.1016/j.biopha.2018.03.111. Epub 2018 Apr 5.
8
Genetic epidemiology of Charcot-Marie-Tooth disease.
Acta Neurol Scand Suppl. 2012(193):iv-22. doi: 10.1111/ane.12013.
9
Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.
J Neurol. 2017 Aug;264(8):1655-1677. doi: 10.1007/s00415-017-8474-3. Epub 2017 Mar 31.

引用本文的文献

1
Symptom clusters after chemoradiotherapy in discharged nasopharyngeal carcinoma patients.
Front Oncol. 2023 Jun 14;13:920889. doi: 10.3389/fonc.2023.920889. eCollection 2023.

本文引用的文献

2
Modeling Drug-Induced Neuropathy Using Human iPSCs for Predictive Toxicology.
Clin Pharmacol Ther. 2017 Jun;101(6):754-762. doi: 10.1002/cpt.562. Epub 2017 Jan 11.
3
Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Oncotarget. 2016 Dec 13;7(50):82244-82253. doi: 10.18632/oncotarget.12545.
4
Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
PLoS One. 2016 Oct 7;11(10):e0164319. doi: 10.1371/journal.pone.0164319. eCollection 2016.
5
Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance).
J Neurol Sci. 2015 Oct 15;357(1-2):35-40. doi: 10.1016/j.jns.2015.06.056. Epub 2015 Jun 27.
6
Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.
Ann Neurol. 2014 Nov;76(5):727-37. doi: 10.1002/ana.24265. Epub 2014 Sep 17.
7
Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment.
Clin Neurol Neurosurg. 2010 Dec;112(10):900-2. doi: 10.1016/j.clineuro.2010.07.005. Epub 2010 Aug 3.
10
Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease.
J Neurol Sci. 2006 Mar 15;242(1-2):47-54. doi: 10.1016/j.jns.2005.11.014. Epub 2005 Dec 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验